CoChat

Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York

Annavajhala, Medini K., Mohri, Hiroshi, Wang, Pengfei, Nair, Manoj, Zucker, Jason E., Sheng, Zizhang, Gomez-Simmonds, Angela, Kelley, Anne L., Tagliavia, Maya, Huang, Yaoxing, Bedford, Trevor, Ho, David D., Uhlemann, Anne-Catrin · 2021

Preprint — published as 10.1038/s41586-021-03908-2 · Paper page

PreprintCited by 137

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Recent months have seen surges of SARS-CoV-2 infection across the globe with considerable viral evolution 1-3 . Extensive mutations in the spike protein may threaten efficacy of vaccines and therapeutic monoclonal antibodies 4 . Two signature mutations of concern are E484K, which plays a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here, we report the emergence of variant lineage B.1.526 that contains E484K and its alarming rise to dominance in New York City in early 2021. This variant is partially or completely resistant to two therapeutic monoclonal antibodies in clinical use and less susceptible to neutralization by convalescent plasma or vaccinee sera, posing a modest antigenic challenge. The B.1.526 lineage has now been reported from all 50 states in the US and numerous other countries. B.1.526 rapidly replaced earlier lineages in New York upon its emergence, with an estimated transmission advantage of 35%. Such transmission dynamics, together with the relative antibody resistance of its E484K sub-lineage, likely contributed to the sharp rise and rapid spread of B.1.526. Although SARS-CoV-2 B.1.526 initially outpaced B.1.1.7 in the region, its growth subsequently slowed concurrent with the rise of B.1.1.7 and ensuing variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.02.23.21252259

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Extended Data Figure 1. Rapid PCR-based screening assay protocol to identify samples harboring key substitutions. (a) Viral RNA is prepared by heat inactivation and centrifugation. The supernatant is then used for the SNP assay, which entails four steps: the reverse transcription (RT) reaction, pre-PCR reading of the plate to assess background fluorescence (SNP pre-read), real-time PCR, and post-PCR reading of the plate to measure fluorescence (SNP post-read). The runtime for this entire protocol is approximately two hours. (b) Genotype at targeted sites in COVID-19 viral RNA can be determined with two MGB probes, one for wild type (conjugated with VIC) and the other for variant type (conjugated with FAM). (c) Example signals for the variant type (K484; blue), the wild type (E484; red) and samples with no signal (black) are shown.
Extended Data Figure 1. Rapid PCR-based screening assay protocol to identify samples harboring key substitutions. (a) Viral RNA is prepared by heat inactivation and centrifugation. The supernatant is then used for the SNP assay, which entails four steps: the reverse transcription (RT) reaction, pre-PCR reading of the plate to assess background fluorescence (SNP pre-read), real-time PCR, and post-PCR reading of the plate to measure fluorescence (SNP post-read). The runtime for this entire protocol is approximately two hours. (b) Genotype at targeted sites in COVID-19 viral RNA can be determined with two MGB probes, one for wild type (conjugated with VIC) and the other for variant type (conjugated with FAM). (c) Example signals for the variant type (K484; blue), the wild type (E484; red) and samples with no signal (black) are shown.CC BY-NC-ND · PubMed Central
Extended Data Figure 2. Flowchart for SARS-CoV-2-positive nasopharyngeal swabs included in this study. (top) During the study period of November 1, 2020 to May 1, 2021, 6,680 patients tested positive for SARS-CoV-2 at our hospital center and affiliated hospitals. From these 9,174 positive nasopharyngeal swabs, 3,433 swabs were stored as part of the Columbia University Biobank COVID-19 sample repository and available for this study. (left) PCR-based genotyping assays for E484K and N501Y (see Extended Data Fig. 1) were performed on 2,345 samples. We identified a significant proportion of samples with E484K (11%), later confirmed through sequencing to primarily fall within the B.1.526 lineage, and a number of samples with N501Y (3.9%), primarily within the B.1.1.7 lineage. (right) We performed whole-genome sequencing on 1,507 samples. Of these, 32% belonged to B.1.526 and the sublineages B.1.526.1 and B.1.526.2, while B.1.1.7 constituted a much smaller proportion of samples at our center (7.5%).
Extended Data Figure 2. Flowchart for SARS-CoV-2-positive nasopharyngeal swabs included in this study. (top) During the study period of November 1, 2020 to May 1, 2021, 6,680 patients tested positive for SARS-CoV-2 at our hospital center and affiliated hospitals. From these 9,174 positive nasopharyngeal swabs, 3,433 swabs were stored as part of the Columbia University Biobank COVID-19 sample repository and available for this study. (left) PCR-based genotyping assays for E484K and N501Y (see Extended Data Fig. 1) were performed on 2,345 samples. We identified a significant proportion of samples with E484K (11%), later confirmed through sequencing to primarily fall within the B.1.526 lineage, and a number of samples with N501Y (3.9%), primarily within the B.1.1.7 lineage. (right) We performed whole-genome sequencing on 1,507 samples. Of these, 32% belonged to B.1.526 and the sublineages B.1.526.1 and B.1.526.2, while B.1.1.7 constituted a much smaller proportion of samples at our center (7.5%).CC BY-NC-ND · PubMed Central
Extended Data Figure 3. Neutralization studies of B.1.526-S477N. (a) Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing S477N alone or all five signature B.1.526-S477N mutations (L5F, T95I, D253G, A701V, and S477N), termed NYΔ5(S477N). Antibodies with emergency use authorization are shown in bold solid lines. Data are represented as mean ± SEM. of technical triplicates and represent one of two independent experiments. (b) Neutralizing activities of convalescent plasma (n=20) against NYΔ5(S477N) as well as against the authentic B.1.526 virus with S477N, and neutralizing activities of vaccinee sera (n=22) against the NYΔ5(S477N) pseudovirus, compared to wildtype counterparts. Statistical comparisons were made using the Wilcoxon matched-pairs signed rank test; two-tailed p-values are reported.
Extended Data Figure 3. Neutralization studies of B.1.526-S477N. (a) Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing S477N alone or all five signature B.1.526-S477N mutations (L5F, T95I, D253G, A701V, and S477N), termed NYΔ5(S477N). Antibodies with emergency use authorization are shown in bold solid lines. Data are represented as mean ± SEM. of technical triplicates and represent one of two independent experiments. (b) Neutralizing activities of convalescent plasma (n=20) against NYΔ5(S477N) as well as against the authentic B.1.526 virus with S477N, and neutralizing activities of vaccinee sera (n=22) against the NYΔ5(S477N) pseudovirus, compared to wildtype counterparts. Statistical comparisons were made using the Wilcoxon matched-pairs signed rank test; two-tailed p-values are reported.CC BY-NC-ND · PubMed Central
Extended Data Figure 4. State-level growth dynamics of B.1.526 and B.1.1.7. Daily state-level frequencies of B.1.526 (in yellow) and B.1.1.7 (in blue), based on GISAID data downloaded on June 6, 2021, were used to plot 7-day sliding window averages of the prevalence of each lineage (shown as dots in the figure). A 4-parameter multinomial logistic regression model was fit directly to the observation data, in which both B.1.1.7 and B.1.526 have parameters specified for frequency at day 0 (January 1, 2021) and logistic growth rate (shown as lines in the figure). States are ordered according to frequency of B.1.526 at the final timepoint of May 8, 2021.
Extended Data Figure 4. State-level growth dynamics of B.1.526 and B.1.1.7. Daily state-level frequencies of B.1.526 (in yellow) and B.1.1.7 (in blue), based on GISAID data downloaded on June 6, 2021, were used to plot 7-day sliding window averages of the prevalence of each lineage (shown as dots in the figure). A 4-parameter multinomial logistic regression model was fit directly to the observation data, in which both B.1.1.7 and B.1.526 have parameters specified for frequency at day 0 (January 1, 2021) and logistic growth rate (shown as lines in the figure). States are ordered according to frequency of B.1.526 at the final timepoint of May 8, 2021.CC BY-NC-ND · PubMed Central
Figure 1. Prevalence of E484K-harboring SARS-CoV-2 and B.1.526. (a) Detection of viruses with key signature mutations in spike over time. The earliest detected E484K-harboring variant was collected in mid-November 2020. The prevalence of E484K (samples with E484K/total PCR-genotyped samples) subsequently increased over time, from 4.8% in early December 2020 up to 24.3% in early March 2021. Throughout late 2020 and early 2021, we identified fewer N501Y-than E484K-harboring isolates, with a maximum of 5.9% of N501Y during mid-February 2021. (b) Distribution of different viral lineages identified by whole genome sequencing. Within our genomic collection (n=1,507), the B.1.526 lineage rose rapidly in early 2021, replacing the majority of other lineages (shown as the white blank space) present during this timeframe. This was followed by a steady rise in B.1.1.7 by mid-2021. The marking below the X axis denotes the time-period used to calculate the growth advantage of B.1.526 over other earlier viruses. (c) Phylogenetic tree of SARS-CoV-2 variants identified by sequencing and alignment of key spike mutations. Unique patterns of spike protein mutations present in genomes sequenced from our hospital center with at least one mutation of interest or concern (E484K, N501Y, S477N, or L452R; n=64) are shown. Residues at which at least one sample harbored a mutation are displayed above the S-protein schematic.
Figure 1. Prevalence of E484K-harboring SARS-CoV-2 and B.1.526. (a) Detection of viruses with key signature mutations in spike over time. The earliest detected E484K-harboring variant was collected in mid-November 2020. The prevalence of E484K (samples with E484K/total PCR-genotyped samples) subsequently increased over time, from 4.8% in early December 2020 up to 24.3% in early March 2021. Throughout late 2020 and early 2021, we identified fewer N501Y-than E484K-harboring isolates, with a maximum of 5.9% of N501Y during mid-February 2021. (b) Distribution of different viral lineages identified by whole genome sequencing. Within our genomic collection (n=1,507), the B.1.526 lineage rose rapidly in early 2021, replacing the majority of other lineages (shown as the white blank space) present during this timeframe. This was followed by a steady rise in B.1.1.7 by mid-2021. The marking below the X axis denotes the time-period used to calculate the growth advantage of B.1.526 over other earlier viruses. (c) Phylogenetic tree of SARS-CoV-2 variants identified by sequencing and alignment of key spike mutations. Unique patterns of spike protein mutations present in genomes sequenced from our hospital center with at least one mutation of interest or concern (E484K, N501Y, S477N, or L452R; n=64) are shown. Residues at which at least one sample harbored a mutation are displayed above the S-protein schematic.CC BY-NC-ND · PubMed Central
Figure 2. Spike protein amino acid substitutions and structural changes represented in sequenced isolates. (a) Maximum-likelihood phylogenetic tree of 2,309 SARS-CoV-2 viruses colored according to spike protein haplotype. Spike protein mutations are labeled on the tree showing the stepwise accumulation of signature B.1.526 mutations T95I, D253G, and L5F, and branching of B.1.526-E484K (green) and two B.1.526-S477N sub-lineages (light orange, blue). The B.1.526-L452R sub-lineage (dark orange) emerged in parallel. An interactive version of this figure is available at https://nextstrain.org/groups/blab/ncov/ny/B.1.526. (b) Key mutations of B.1.526 displayed on the spike trimer. The D253G mutation resides in the antigenic supersite within the N-terminal domain (NTD), a target for neutralizing antibodies, E484K and S477N at the receptor binding domain (RBD) interface with the cellular receptor ACE2, and A701V near the furin cleavage site.
Figure 2. Spike protein amino acid substitutions and structural changes represented in sequenced isolates. (a) Maximum-likelihood phylogenetic tree of 2,309 SARS-CoV-2 viruses colored according to spike protein haplotype. Spike protein mutations are labeled on the tree showing the stepwise accumulation of signature B.1.526 mutations T95I, D253G, and L5F, and branching of B.1.526-E484K (green) and two B.1.526-S477N sub-lineages (light orange, blue). The B.1.526-L452R sub-lineage (dark orange) emerged in parallel. An interactive version of this figure is available at https://nextstrain.org/groups/blab/ncov/ny/B.1.526. (b) Key mutations of B.1.526 displayed on the spike trimer. The D253G mutation resides in the antigenic supersite within the N-terminal domain (NTD), a target for neutralizing antibodies, E484K and S477N at the receptor binding domain (RBD) interface with the cellular receptor ACE2, and A701V near the furin cleavage site.CC BY-NC-ND · PubMed Central
Figure 3. Neutralization studies of B.1.526-E484K and comparative analyses. (a) Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing E484K alone or all five signature B.1.526 mutations (L5F, T95I, D253G, A701V, and E484K), termed NYΔ5(E484K) as well as against the authentic B.1.526-E484K. Antibodies with emergency use authorization are shown in bold solid lines. Data are represented as mean ± SEM of technical triplicates and represent one of two independent experiments. (b) Neutralizing activities of convalescent plasma (n=20) and vaccinee sera (n=22) against the NYΔ5(E484K) pseudovirus compared to wildtype pseudovirus as well as against authentic B.1.526-E484K and wildtype virus (WA1). (c) Fold change in convalescent plasma and vaccinee sera neutralization ID50 of different variant pseudoviruses and live viruses compared to wildtype counterparts. The data on B.1.1.7, B.1.351 and P.1 were derived from our prior publications4,18. Data from 20 convalescent patients or 22 vaccinated individuals were averaged and are represented as arithmetic mean ± SEM (individual data points also shown). Statistical comparisons were made using the Wilcoxon matched-pairs signed rank test; two-tailed p-values are reported.
Figure 3. Neutralization studies of B.1.526-E484K and comparative analyses. (a) Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing E484K alone or all five signature B.1.526 mutations (L5F, T95I, D253G, A701V, and E484K), termed NYΔ5(E484K) as well as against the authentic B.1.526-E484K. Antibodies with emergency use authorization are shown in bold solid lines. Data are represented as mean ± SEM of technical triplicates and represent one of two independent experiments. (b) Neutralizing activities of convalescent plasma (n=20) and vaccinee sera (n=22) against the NYΔ5(E484K) pseudovirus compared to wildtype pseudovirus as well as against authentic B.1.526-E484K and wildtype virus (WA1). (c) Fold change in convalescent plasma and vaccinee sera neutralization ID50 of different variant pseudoviruses and live viruses compared to wildtype counterparts. The data on B.1.1.7, B.1.351 and P.1 were derived from our prior publications4,18. Data from 20 convalescent patients or 22 vaccinated individuals were averaged and are represented as arithmetic mean ± SEM (individual data points also shown). Statistical comparisons were made using the Wilcoxon matched-pairs signed rank test; two-tailed p-values are reported.CC BY-NC-ND · PubMed Central
Figure 4. Spread of lineages B.1.1.7 and B.1.526 in New York and the USA. (a, b) Frequencies of lineages B.1.1.7 (blue) and B.1.526 (yellow) in the CUIMC catchment area (in panel a) and New York State (in panel b) with dots representing daily 7-day sliding window averages and lines representing fit to a multinomial logistic regression model. (c) Ternary plot of state-level frequency trajectories for 42 states separating frequencies of B.1.1.7, B.1.526 and other lineages. Each state-level trajectory is a line in this plot moving from lower left in January 2021 when both B.1.1.7 and B.1.526 were rare, rightward as B.1.1.7 and B.1.526 increase in frequency. The trajectory of New York State is highlighted in purple. (d) The same data as in panel c, except plotting frequency of B.1.1.7 against logistic growth rate of B.1.526. (e) Phylogenetic tree of 933 B.1.526 samples from across the US where branch tips are colored based on location of sampling and branches are colored by inferred ancestral location. (f) Phylogeographic view of data from panel e, where each sampling location is represented as a circle with area proportional to sample count and each inferred transition event across the phylogeny is drawn as an arc connecting inferred origin and destination. Most migration events are inferred to be direct dispersals from New York State.
Figure 4. Spread of lineages B.1.1.7 and B.1.526 in New York and the USA. (a, b) Frequencies of lineages B.1.1.7 (blue) and B.1.526 (yellow) in the CUIMC catchment area (in panel a) and New York State (in panel b) with dots representing daily 7-day sliding window averages and lines representing fit to a multinomial logistic regression model. (c) Ternary plot of state-level frequency trajectories for 42 states separating frequencies of B.1.1.7, B.1.526 and other lineages. Each state-level trajectory is a line in this plot moving from lower left in January 2021 when both B.1.1.7 and B.1.526 were rare, rightward as B.1.1.7 and B.1.526 increase in frequency. The trajectory of New York State is highlighted in purple. (d) The same data as in panel c, except plotting frequency of B.1.1.7 against logistic growth rate of B.1.526. (e) Phylogenetic tree of 933 B.1.526 samples from across the US where branch tips are colored based on location of sampling and branches are colored by inferred ancestral location. (f) Phylogeographic view of data from panel e, where each sampling location is represented as a circle with area proportional to sample count and each inferred transition event across the phylogeny is drawn as an arc connecting inferred origin and destination. Most migration events are inferred to be direct dispersals from New York State.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 137

Metadata

Authors
Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., Bedford, T., Ho, D. D., & Uhlemann, A.-C.
Publisher
openRxiv
Published
2021-02-25
References
20
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York. https://app.cochat.ai/papers/10.1101/2021.02.23.21252259
The paper
Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., Bedford, T., Ho, D. D., & Uhlemann, A.-C. (2021). Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York. https://doi.org/10.1101/2021.02.23.21252259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.